Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus ZAGAM.
FLOXIN IN DEXTROSE 5% vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg intravenously every 12 hours.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
10-12 hours; prolonged in renal impairment
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic